SIR, A small number of reports have implicated infliximab as an aetiological factor in the
development of lung inflammation and fibrosis in patients with rheumatoid arthritis [1–5] …

The tumor necrosis factor α (TNFα) inhibitors infliximab, etanercept, and adalimumab are
nowadays widely used in the treatment of rheumatoid arthritis (RA). Side effects are mostly …

A 78-year-old man with an 18-year history of rheumatoid arthritis (RA) was treated with
tumor necrosis factor (TNF)-α inhibitor adalimumab. Chest computed tomography showed a …

Interstitial lung disease is one of the most common and severe extra-articular manifestations
associated with rheumatoid arthritis. Previous to the biologic treatment era, methotrexate …

A 70-year-old woman with a 6-year history of seropositive rheumatoid arthritis (RA) and
asymptomatic interstitial lung disease (ILD) began taking etanercept for ongoing arthritis …

Discussion Previous case reports have suggested a possible higher risk of precipitation of
'methotrexate pneumonitis' when infliximab is added to methotrexate (3–5). There have also …

SIR, Acute deterioration of pre-existing rheumatoid arthritis interstitial lung disease (RA-ILD)
or development of new-onset rapid-fibrosing alveolitis has been reported for each of the …

A 60-year-old woman with rheumatoid arthritis had 4 pulmonary rheumatoid nodules with
unchanged size since 1999 that appeared during methotrexate (MTX) treatment (Figure 1A) …

Two patients with rheumatoid arthritis (RA) that developed serious infectious complications
following anti-TNFα therapy (infliximab) are reported. Patient 1 developed tuberculosis with …

SIR, Interstitial lung disease (ILD) has been reported in the literature following treatment with
anti-TNF, but never before with certolizumab pegol. We report a case of a 71-year-old lady …